Trupanion, Inc. — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
Trupanion provides medical insurance for cats and dogs in the United States, Canada, Continental Europe, and Australia. The company reports subscription business and other business segments. This unaudited quarterly report covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023.
Financial Performance and Key Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $306.1 million | $256.3 million | +19% |
| Subscription revenue | $201.1 million | $165.2 million | +22% |
| Other business revenue | $105.0 million | $91.1 million | +15% |
| Gross profit | $36.2 million | $26.3 million | +38% |
| Gross margin | 11.8% | 10.3% | +1.5 percentage points |
| Operating loss | $6.1 million | $24.5 million | Improved by $18.3 million |
| Net loss | $6.9 million | $24.8 million | Improved by $17.9 million |
| Net loss per diluted share | $0.16 | $0.60 | Improved |
| Operating cash flow | $2.4 million | $(6.9) million | Improved by $9.3 million |
Cost of revenue was $269.9 million, or 88% of revenue, compared with 90% in the prior-year quarter. Operating expenses were $42.3 million, or 14% of revenue, compared with $50.8 million, or 20%, previously. Interest expense increased 51% to $3.6 million, partly offset by $2.8 million of net other income, primarily reflecting investment income.
Total pets enrolled at period end were 1.708 million, up 6% year over year. Subscription pets enrolled were 1.006 million, up 11%. Monthly average revenue per pet increased 10% to $69.79, while average monthly retention declined to 98.41% from 98.65%. Average pet acquisition cost declined to $207 from $247, and new pet acquisition expense declined 22% to $16.8 million.
At March 31, 2024, cash and cash equivalents were $146.5 million, short-term investments were $128.7 million, and long-term investments were $13.0 million. Cash, cash equivalents, and restricted cash totaled $169.6 million. Accounts receivable were $278.5 million and deferred revenue was $249.1 million.
Debt consisted principally of $135.0 million of term loans under the secured Credit Facility. The carrying value of current and long-term debt was approximately $128.8 million, with $132.95 million of principal payments scheduled through 2028. The stated interest rate was approximately 10.46% at March 31, 2024. The company was in compliance with all debt covenants and had $15.0 million of revolving borrowing capacity available.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven by higher subscription pet months, a 10% increase in monthly average revenue per pet, and growth in the other business segment.
- Subscription business cost of revenue improved to 86% of segment revenue from 88%, while other business cost of revenue increased to 93% from 92%.
- Veterinary invoice expense increased 20% overall to $233.6 million. Subscription veterinary expense per pet month increased 6%, while other business veterinary expense per pet month increased 23%.
- General and administrative expense decreased 30%, primarily because Q1 2023 included a $4.8 million stock-based compensation charge associated with executive departures and a $3.8 million settlement related to uncollected premiums.
- Stock-based compensation expense declined 34% to $8.2 million, but remained a significant expense.
- Operating cash flow turned positive, although cash, cash equivalents, and restricted cash declined by $0.9 million during the quarter.
- Subscription business operating loss narrowed to $4.5 million from $18.8 million; other business operating loss narrowed to $1.5 million from $5.6 million.
Outlook, Commentary, Risks, and Unusual Items
Management stated that cash provided by operations, existing cash and investments, and available Credit Facility borrowings are expected to be sufficient to fund operations and capital requirements for the next 12 months. Management may seek additional equity, equity-linked, or debt financing to support growth or strategic opportunities, but such financing may not be available on acceptable terms.
As of March 31, 2024, insurance entities held $237.1 million of cash, cash equivalents, and short-term investments. Their capital surplus was $256.7 million, or $103.4 million above estimated risk-based capital requirements. Regulatory restrictions may limit the timing or amount of capital distributions to the parent company. In April 2024, the parent company received an $8.6 million dividend from WICL Segregated Account AX.
The company expects changes to the other business segment over time, including a potential roll-off of a portion of that business beginning in 2025. The timing and extent are not controlled by Trupanion and could affect revenue, margins, capital requirements, and operating results.
Key operating risks include continued net losses, veterinary cost inflation, reserve estimation risk, regulatory approval and timing for pricing changes, retention deterioration, competition, reliance on veterinarians and third-party distribution partners, international and foreign-exchange exposure, debt service and floating interest rates, insurance capital requirements, cybersecurity and technology risks, and potential changes in the other business segment.
The reserve for veterinary invoices was $62.3 million at March 31, 2024. Management recorded unfavorable reserve development of approximately $0.9 million during the quarter, reflecting ongoing analysis of payment trends. Legal proceedings may arise in the ordinary course of business, but management did not believe currently identified matters were material individually or in the aggregate.
Disclosure controls and internal control over financial reporting were not effective because of previously disclosed material weaknesses involving information technology general controls and transaction processing performed by an unaffiliated general agent. Management performed additional procedures and concluded that the financial statements fairly present the company’s financial position and results under U.S. GAAP. Remediation efforts are ongoing and are not complete.
The filing identifies Margi Tooth’s appointment as chief executive officer effective August 1, 2024, succeeding founder Darryl Rawlings, who is expected to remain chairperson. The filing does not provide a clear numerical full-year financial guidance range in the text provided.
Most Important Facts for Investors to Verify
- Whether revenue growth, improved subscription margins, lower acquisition costs, and positive operating cash flow continue in subsequent quarters.
- Whether average monthly retention remains near 98.4% and whether monthly average revenue per pet continues to offset rising veterinary costs.
- The adequacy of the $62.3 million veterinary invoice reserve and the effect of future reserve development or veterinary inflation.
- Compliance with the Credit Facility’s covenants, the impact of approximately 10.46% floating-rate debt, and the scheduled 2027–2028 principal maturities.
- The extent and timing of the expected 2025 roll-off in the other business segment and its effect on revenue, margins, and regulatory capital.
- Progress toward remediating the material weaknesses in internal control over financial reporting.
- Regulatory restrictions on insurance subsidiary capital and the company’s ability to transfer excess capital or dividends to the parent.
- The execution and potential business impact of the August 2024 CEO transition.